USFDA completes GMP inspection at packaging facility of Granules India’s arm

04 Dec 2025 Evaluate

U.S. Food and Drug Administration (USFDA) has successfully completed a GMP inspection at packaging facility of Granules India’s US step-down subsidiary -- Granules Consumer Health, LLC with zero observations. This was the facility’s second FDA inspection, following the March 2023 audit that resulted in a No Action Indicated (NAI) classification. 

Granules Consumer Health serves as Granules’ front-end division for OTC products in the U.S., leveraging Granules India’s manufacturing efficiencies, regulatory compliance, and integrated supply chain.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

560.25 -6.30 (-1.11%)
05-Dec-2025 09:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.50
Dr. Reddys Lab 1277.95
Cipla 1517.20
Zydus Lifesciences 935.00
Lupin 2091.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×